Yuhan Corporation’s licensed-out non-alcoholic steatohepatitis drug to start phase 1 clinical trial in Europe
Expected to receive 10 million USD as a milestone payment Yuhan Corporation (000100. KS) announced on the 17th of November that the new drug candidate (YH25724) for the treatment of non-alcoholic steatohepatitis (NASH), which was licensed-out to Boehringer Ingelheim, has entered a phase 1 clinical trial in Europe. The two companies plan to evaluate safety, […]